Description
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company") today announced that Fidelity Management & Research Company ("Fidelity") has led a new round of investment in Dragonfly, along with other major investors. This brings total equity funding plus partnership capital in the Company to over $300 million thus far, with potential future milestones of over $10 billion plus ongoing royalties.